1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92. ROP caused by over oxygenation in NICU babies
2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
3. Ehrenfeld JM et al. Continuous Non-invasive Hemoglobin Monitoring during Orthopedic Surgery: A Randomized Trial. J Blood Disorders Transf. 2014. 5:9. 2.
4. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
5.As ranked in the 2024 Newsweek world's Best Hospitals Listing http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview
6. Estimate: Masimo data on file.
7. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at https://www.masimo.com/. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
8. Masimo Stork™ is not intended to replace the monitoring, diagnosis, or treatment provided by a physician or healthcare provider. Masimo Stork™ is not intended for use with infants and neonates previously diagnosed with cardiovascular or respiratory disease or conditions. For use with healthy infants 0 to 18 months of age and between 6 to 30 lbs.
Phone not included.
PLCO-007410/PLM-14532B-0724